Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 7, 2014, Pages 648-658

  Li, Shen ^a   Liang, Jingyan ^b   Niimi, Manabu ^a   Waqar, Ahmed Bilal ^a   Kang, Dedong ^a   Koike, Tomonari ^c   Wang, Yingge ^d   Shiomi, Masashi ^c   Fan, Jianglin ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NAGANO COLLEGE OF NURSING   (Japan)

^c KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d YANGZHOU UNIVERSITY   (China)

Author keywords

Coronary artery; Hypercholesterolemia; Probucol; Stability; WHHL rabbits

Indexed keywords

ATORVASTATIN; GELATINASE B; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; INTERSTITIAL COLLAGENASE; LIPID; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; PROBUCOL; PYRROLE DERIVATIVE;

ANIMAL; BLOOD; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; HYPERLIPOPROTEINEMIA TYPE II; MACROPHAGE; MALE; METABOLISM; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; PLAQUE, ATHEROSCLEROTIC; PROBUCOL; PYRROLES; RABBITS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84905168279     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.21600     Document Type: Article

References (26)

1. Weber C, Noels H: Atherosclerosis: current pathogenesis and therapeutic options. Nat Med, 2011; 17: 1410-1422.
2. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets I: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435.
3. Libby P, Aikawa M: Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med, 2002; 8: 1257-1262.
4. Kesaniemi YA, Grundy SM: Influence of probucol on cholesterol and lipoprotein metabolism in man. J Lipid Res, 1984; 25: 780-790.
5. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A, 1987; 84: 5928-5931.
6. Daugherty A, Zweifel BS, Schonfeld G: Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol, 1989; 98: 612-618.
7. Carew TE, Schwenke DC, Steinberg D: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A, 1987; 84: 7725-7729.
8. Kasai T, Miyauchi K, Kubota N, Kajimoto K, Amano A, Daida H: Probucol therapy improves long-term (10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis, 2012; 220: 463-469.
9. Yamashita S, Matsuzawa Y: Where are we with probucol: a new life for an old drug? Atherosclerosis, 2009; 207: 16-23.
10. Siveski-Iliskovic N, Kaul N, Singal PK: Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation, 1994; 89: 2829-2835.
11. Brasen JH, Koenig K, Bach H, Kontush A, Heinle H, Witting PK, Yla-Herttuala S, Stocker R, Beisiegel U: Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. Atherosclerosis, 2002; 163: 249-259.
12. Fruebis J, Gonzalez V, Silvestre M, Palinski W: Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptordeficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol, 1997; 17: 1289-1302.
13. Baker SG, Joffe BI, Mendelsohn D, Seftel HC: Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J, 1982; 62: 7-11.
14. Yamamoto A, Matsuzawa Y, Kishino B, Hayashi R, Hirobe K, Kikkawa T: Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis, 1983; 48: 157-166.
15. Shiomi M, Ito T, Yamada S, Kawashima S, Fan J: Development of an animal model for spontaneous myocardial infarction (WHHLMI rabbit). Arterioscler Thromb Vasc Biol, 2003; 23: 1239-1244.
16. Wang Y, Niimi M, Nishijima K, Yu Y, Koike T, Kitajima K, Inoue T, Waqar AB, Liu E, Kohashi M, Ketamura Y, Yoshikawa T, Zhang J, Ma L, Zha X, Watanabe T, Asada Y, Chen EY, Fan J: Human apolipoprotein AII protects against diet-induced atherosclerosis in transgenic rabbits. Arterioscler Thromb Vas Biol, 2013; 33: 224-231.
17. Liang J, Liu E, Yu Y, Kitajima S, Koike T, Jin Y, Morimoto M, Hatakeyama K, Asada Y, Watanabe T, Sasaguri Y, Watanabe S, Fan J: Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation, 2006; 113: 1993-2001.
18. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1995; 92: 1355-1374.
19. Yu Y, Koike T, Kitajima S, Liu E, Morimoto M, Shiomi M, Hatakeyama K, Asada Y, Wang KY, Sasaguri Y, Watanabe T, Fan J: Temporal and quantitative analysis of expression of metalloproteinases (MMPs) and their endogenous inhibitors in atherosclerotic lesions. Histol Histopathol, 2008; 23: 1503-1516.
20. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med, 1989; 320: 915-924.
21. Wu BJ, Di Girolamo N, Beck K, Hanratty CG, Choy K, Hou JY, Ward MR, Stocker R: Probucol [4,4'-[(1-methylethylidene) bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. J Pharmacol Exp Ther, 2007; 321: 477-484.
22. Wu TC, Chen YH, Leu HB, Chen YL, Lin FY, Lin SJ, Chen JW: Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and-9 in experimental atherosclerosis. Free Radic Biol Med, 2007; 43: 1508-1522.
23. Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, Rader DJ: Pharmacologic suppression of hepatic ATPbinding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Circulation, 2011; 124: 1382-1390.
24. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K, Japan Atherosclerosis S: Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan--2012. J Atheroscler Thromb, 2013; 20: 603-615.
25. Adhikari BK, Meng X: Challenges of PAS therapy for coronary atherosclerotic plaque reversal. Heart, 2012; 98: E167.
26. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Longterm probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2008; 15: 292-303